Truist Keeps Buy on Hinge Health, Sets $63 Target After Strong Q4 2025 Results
Truist Securities reaffirmed its Buy rating on Hinge Health Inc (HNGE) and set a $63 price target after the company released fourth-quarter 2025 results. The target implies sizable upside from the stock's current price of $37 and sits within a broader analyst range of $48 to $72. Management discussion and analyst commentary highlighted accelerating…